GLSI (Greenwich LifeSciences) Current Accrued Expense: $0.05 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GLSI Greenwich LifeSciences Inc GLSI
35 GF Score
Price $14.33
! 1 Warning Sign
View Full Analysis

What is Greenwich LifeSciences Current Accrued Expense?

Greenwich LifeSciences GLSI +0.84% 35 Current Accrued Expense is $0.05 Mil as of Mar. 2026. GuruFocus rates GLSI with a GF Score™ of 35/100. The stock has 1 warning sign investors should review.

Greenwich LifeSciences's Current Accrued Expense for the quarter that ended in Mar. 2026 was $0.05 Mil.

Greenwich LifeSciences's quarterly Current Accrued Expense increased from Sep. 2025 ($0.21 Mil) to Dec. 2025 ($0.28 Mil) but then declined from Dec. 2025 ($0.28 Mil) to Mar. 2026 ($0.05 Mil).

Greenwich LifeSciences's annual Current Accrued Expense increased from Dec. 2023 ($0.04 Mil) to Dec. 2024 ($0.08 Mil) and increased from Dec. 2024 ($0.08 Mil) to Dec. 2025 ($0.28 Mil).

Greenwich LifeSciences Current Accrued Expense Related Terms

Greenwich LifeSciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Greenwich LifeSciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Greenwich LifeSciences Current Accrued Expense Chart

Greenwich LifeSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial 0.16 0.04 0.04 0.08 0.28

Greenwich LifeSciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.08 0.21 0.28 0.05
GLSI
35GF Score
Greenwich LifeSciences Inc GLSI
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Greenwich LifeSciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.05 Mil mean?
Greenwich LifeSciences (GLSI) has a Current Accrued Expense of $0.05 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Greenwich LifeSciences and its competitors.
Is Greenwich LifeSciences' Current Accrued Expense too high?
Greenwich LifeSciences' current Current Accrued Expense is $0.05 Mil. Overall, Greenwich LifeSciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Greenwich LifeSciences' Current Accrued Expense compare to PLX and DTIL?
Greenwich LifeSciences' Current Accrued Expense of $0.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Greenwich LifeSciences and its competitors. Greenwich LifeSciences's current Current Accrued Expense is $0.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Greenwich LifeSciences stock overvalued right now?
Greenwich LifeSciences (GLSI) has a current Current Accrued Expense of $0.05 Mil. The current Current Accrued Expense is $0.05 Mil. Greenwich LifeSciences' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Greenwich LifeSciences (GLSI), the current Current Accrued Expense is $0.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Greenwich LifeSciences Business Description

Address 3992 Bluebonnet Drive, Building 14, Stafford, TX, USA, 77477
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
35GF Score

Get the complete analysis for GLSI

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.33
Price